

## UKCGG-National Cancer Genetics MDT meeting: 17th September 2026

### Caution, standard practice may not apply: issues of atypical penetrance - lead by RMH

Meeting contact: Terri McVeigh/Alice Garrett

Thank you to everyone who attended this session. Below is a summary of the presented cases and relevant publications and resources to refer to.

### Presented Topics

|        |                                                                                                                                                                                                                                                                                                                           |                                                                                                                           |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| 1      |  <p><b>National audit of thyroid surveillance and outcomes to assess variation and barriers</b></p>                                                                                                                                     | <p>Presented by:<br/>Roshani Patel<br/>St George's Hospital<br/>Roshani.patel@stgeorges.nhs.uk</p>                        |
|        | <p>Actions/Outcome: Any centres interested in participating to register interest using QR code above or contact Roshani Patel</p>                                                                                                                                                                                         |                                                                                                                           |
| Case 2 | <p><b>Overview of CanVIG-UK reduced (atypical) penetrance and variant reclassification frameworks</b></p>                                                                                                                                                                                                                 | <p>Presented by:<br/>Alice Garrett<br/>St George's Hospital/Institute of Cancer Research<br/>Alice.garrettt@icr.ac.uk</p> |
|        | <p>Actions/Outcome: Current frameworks available at: <a href="https://www.cangene-canvaruk.org/canvig-uk-guidance">https://www.cangene-canvaruk.org/canvig-uk-guidance</a>, both frameworks currently under review for update by CanVIG-UK, reclassification framework to include atypical penetrance classifications</p> |                                                                                                                           |
| Case 3 | <p><b>Current status of UKCGG guidance for clinical management of reduced/atypical penetrance variants in <i>BRCA1/2</i>, <i>TP53</i> and Lynch Syndrome</b></p>                                                                                                                                                          | <p>Presented by:<br/>Terri McVeigh<br/>Royal Marsden Hospital<br/>Terri.Mcveigh@rmh.nhs.uk</p>                            |
|        | <p>Actions/Outcome: UKCGG <i>BRCA1/2</i> statement already published on UKCGG website, <i>TP53</i> guidance under development (has been circulated to clinical leads), Lynch syndrome guidance development starting now</p>                                                                                               |                                                                                                                           |
| Case 4 | <p><b><i>BRCA1</i> c.5153-26A&gt;G – evolving variant classifications in the ultimate tricky case</b></p>                                                                                                                                                                                                                 | <p>Presented by:<br/>Elizabeth Johnston<br/>Nottingham genetics lab<br/>elizabeth.johnston11@nhs.net</p>                  |
|        | <p>Actions/Outcome: Variant reclassified from VUS to likely pathogenic with reduced penetrance, alert issued via CanVar-UK discussion forum and labs reissuing reports</p>                                                                                                                                                |                                                                                                                           |

|        |                                                                                                                                                               |                                                                                                                 |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| Case 5 | Exemplar cases involving atypical penetrance and reclassification with polls                                                                                  | Presented by:<br>Alice Garrett<br>St George's Hospital/Institute of Cancer Research<br>Alice.garrettt@icr.ac.uk |
|        | Actions/Outcome: UKCGG/CanVIG-UK to continue work on management guidance for carriers of atypical penetrance variants in <i>TP53</i> and Lynch syndrome genes |                                                                                                                 |

### **Relevant publications/resources**

| Topic                                                                                | Link                                                                                                                                                                                                                                                                            |
|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CanVIG-UK reduced penetrance framework                                               | <a href="#">Classification of variants of reduced penetrance in high-penetrance cancer susceptibility genes: Framework for genetics clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group-UK) - Genetics in Medicine</a>                         |
| CanVIG-UK reclassification framework                                                 | <a href="#">Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK) - Genetics in Medicine</a>                                                                |
| UKCGG statement on management of carriers of atypical penetrance variants in BRCA1/2 | <a href="https://www.ukcgg.org/media/12938/ukcgg-cstag-statement-regarding-clinical-management-of-carriers-of-non-standard-penetrance.pdf">https://www.ukcgg.org/media/12938/ukcgg-cstag-statement-regarding-clinical-management-of-carriers-of-non-standard-penetrance.pdf</a> |

**Please send any questions or ideas for future meetings to  
[UKCGGNationalMDT@icr.ac.uk](mailto:UKCGGNationalMDT@icr.ac.uk)**